SCHEMBL6220175

SCHEMBL6220175

FCC1(CCl)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2889655 0.78
SCHEMBL23829897 0.78
SCHEMBL21617020 0.73
SCHEMBL9397043 0.67
SCHEMBL21273830 0.67
SCHEMBL19504229 0.67
SCHEMBL23287245 0.67
SCHEMBL1752414 0.67
SCHEMBL24931632 0.66
SCHEMBL9636022 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1102767-B1 SUBSTITUTED PYRAZOLE DERIVATIVES BAYER HEALTHCARE AG (DE) 2005-11-02 EP disclosed
US-6833364-B1 Inhibiting degradation of cyclic guanosine monophosphate; cardiovascular disorders; such as 3-(4-amino-5-cyclopropyl-pyrimidin-2-yl)-1-(2-fluorobenzyl)1H-pyrazolo-(3,4 -b)-pyridine BAYER HEALTHCARE AG (DE) 2004-12-21 US disclosed
EP-1102767-A1 SUBSTITUTED PYRAZOLE DERIVATIVES Bayer Aktiengesellschaft (DE) 2001-05-30 EP disclosed
WO-2000006568-A1 SUBSTITUTED PYRAZOLE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2000-02-10 WO disclosed